

REMARKS/ARGUMENTS

Claims 1-28 are canceled.

Claims 29 – 38 are new.

Support for each new claim is found at the originally filed claims and throughout the specification.

Upon entry of the amendment, Claims 29-38 will be active.

No new matter is believed to have been added.

Applicants thank Examiner Ha for indicating that Claims 16 and 17 would be allowable if rewritten in independent form, including all of the limitations of the base claim and any intervening claims.

All objections and rejections are obviated by cancellation of Claims 1-28.

The new claims have, as a feature, at least one cyclic peptide of SEQ ID NO: 18.

Accordingly, it is believed that the new claims are allowable. Early notification to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



Charles J. Andres, Jr., Ph.D.
Attorney of Record
Registration No. 57,537

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 08/07)